Blepharitis is a common eye condition characterized by irritated, flaky, and itchy eyelids. It involves the base of the eyelashes and/or eyelid margins. Some of the key symptoms include eye redness, burning sensation, watery eyes, and sensitivity to light. Blepharitis can occur due to various factors such as excessive dryness, bacterial or allergen exposure, underlying skin conditions like rosacea or seborrheic dermatitis. The available treatment options aim to reduce inflammation, manage symptoms, and prevent recurrences. This includes warm compresses, eyelid scrubs, artificial tears, antibiotics, steroids, antidepressants, and omega-3 supplements.
The global blepharitis treatment market is estimated to be valued at US$ 2.5 Bn in 2024 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030.
Key factors driving the market include rising prevalence of blepharitis, growing awareness about the condition and its treatment, and launch of novel treatment therapies.
Key Takeaways
Key players operating in the blepharitis treatment market include Scope Ophthalmic Ltd., NovaBay Pharmaceuticals Inc., Thea Pharmaceuticals Ltd., Perrigo Laboratories, InSite Vision Incorporated, Merck & Co., and Novartis AG.
Rising awareness about blepharitis and its numerous symptoms is boosting the demand for various treatment options across the globe. However, lack of acknowledgement about the condition remains a major challenge.
Development of novel drug formulations and treatment techniques are accelerating the growth of blepharitis treatment market. Players are increasingly focusing on development of combination therapies, controlled-release formulations, and therapies that are less reliant on antibiotic usage.
Market Trends
Increasing adoption of antibiotic-sparing treatments- Growing concerns about antibiotic resistance have prompted players to develop treatments that do not involve antibiotic usage. Players are exploring alternatives such as tear functional lipid emulsion therapies, bacteriophage therapies, etc.
Focus on combination therapies- Combining different treatment modalities such as warm compresses, lid scrubs, and topical therapies is gaining popularity for managing persistent or chronic blepharitis. Players are introducing fixed-dose combination products for enhanced compliance and outcomes.
Market Opportunities
Underpenetrated emerging markets- Markets in Asia Pacific, Latin America, Middle East and Africa currently account for a minimal share and offer lucrative growth opportunities. With improving access and awareness, these regions will likely witness faster uptake of blepharitis treatments.
Novel drug delivery systems- Development of advanced delivery platforms such as controlled-release gels, inserts, and biodegradable implants can help overcome challenges linked to conventional eye drop formulations. This can boost treatment outcomes.
Impact of COVID-19 on Blepharitis Treatment Market Growth
The COVID-19 pandemic has significantly impacted the growth of the blepharitis treatment market. During the initial lockdown phases, doctor consultations and non-essential medical procedures were postponed or delayed, thus restricting market growth. However, as the pandemic unfolded, treatment for chronic diseases including blepharitis continued through teleconsultations and home delivery of medicines.
While the demand for over-the-counter treatments like eyelid scrubs and warm compresses increased during the pandemic, sales of prescription drugs like topical antibiotics and steroids declined owing to deferred in-person consultations. Vaccination drives and introduction of new treatment guidelines focusing on chronic disease management have helped resume regular eye care post pandemic.
With rising awareness about eye hygiene to prevent viral transmission, the blepharitis treatment market is projected to regain lost growth momentum in the forecast period. Market players are also launching new single-use compresses and convenient packaging formats to boost product usage from homes. E-pharmacies and tele-ophthalmology are likely to play an important role for continued blepharitis management in the post-pandemic period.
Geographical Regions with Highest Blepharitis Treatment Market Value
North America represents the largest regional market for blepharitis treatment in terms of value, accounting for over 40% share currently. This is attributed to high blepharitis prevalence, strong healthcare infrastructure and greater affordability of treatment options in the US and Canada.
Within North America, the US market holds the major value share due to the presence of leading pharmaceutical companies, favourable reimbursement policies, and rising blepharitis-related doctor visits across different age groups over the last decade.
Asia Pacific is emerging as the fastest growing regional market for blepharitis treatment worldwide. Rapid economic development, growing medical tourism, increasing healthcare spending capacity and large patient pool are driving higher blepharitis diagnosis and management rates in countries like India, China and South Korea.
With a fifth of global population, improved living standards and changing lifestyles leading to genetic disorders, Asia Pacific is expected to offer lucrative growth opportunities for blepharitis treatment market players over the coming years.
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/
